By Ameen Kamal
WHEN Prime Minister Tan Sri Mahiaddin Yassin announced the National Recovery Plan on June 15, he mentioned the target of the country achieving herd immunity by the end of this year with a significant increase of vaccination rate.
Assuming the target is 27 million people (82.5 per cent of the local population) and 2.96 million foreigner population whereby each person requires 2 doses, Malaysia would need to utilise 59.92 million doses.
The entire vaccine doses need to completely administered between October to November this year, and this can only be achieved under an “increasing vaccination rate scenario” which has been generally mentioned as a target by the Prime Minister as well as the Minister in-charge of the National Immunisation programme.
Under this scenario, a potential increasing rate scenario (in terms of daily average administered doses per month) could be projected as such: 150,000 in the second half of June, 250,000 in July, 350,000 in August, and 400,000 from September onwards (which is assumed here as the ceiling capacity).
For “herd immunity” to be achieved, an additional two months may be added on top of the projected completion time (October-November) to utilise all of the 59.92 million doses.
This is because the second dose is roughly three weeks after the first, and given that immunity could take three to four weeks to “kick-in” after the second dose, another three to four weeks should also be added.
Therefore, a ball park period of two months is needed to be assumed after completion of doses administration to consider reaching the targeted herd immunity status.
With increased number of vaccination centres and decentralisation strategies such as empowering general practitioner clinics, private institutions, drive-through centres and use of government vehicles for vaccination campaigns to reach rural areas and elderlies, it will increase the vaccination capacity greatly.
However, in order for this figure to be sustained daily and increased as per the projection, two biggest bottlenecks could be vaccine shipments and local registrations.
The “increasing rate scenario” above would need the corresponding minimum vaccine doses (in millions of doses per month) of about 2.55 million for the second half of June, 7.75, 10.85, 12.4 and 1.99 million doses for the months of July, August, September, October, and November respectively.
Given that we have ordered up to 125% of the population, and assuming deliveries are on schedule, then we should have a surplus (above the assumed herd immunity target above) by November onwards.
But just because we have ordered above 100% of our population, it doesn’t solve the speed issue.
Unprecedented times require unprecedented measures, and the authorities should explore all options to ensure timely vaccine delivery.
If for whatever reason we are not able to increase vaccination rate, a “flat rate” (instead of an increasing rate) of say, an average 200,000 vaccine daily administered doses can set the target back to the second quarter next year.
As for registrations, there could be two scenarios. If the registration rate is not flattening and is more than vaccine supply, then its business-as-usual. However, if vaccine supply is more than registration and data is plateauing, say, by end of August (as the cut-off period to observe and confirm the trend), then automatic registrations may have to be considered.
Automatic registrations, or “jab-first-register later” strategies may face public backlash, especially without proper communications with the public. This should only be considered with really strong reasonings and circumstances that can be effectively communicated with the public.
Several unknowns remain. We can’t just assume everyone receiving vaccines will develop sufficient immunity and for a sufficient amount of time. Pharmacovigilance post vaccination needs to account for monitoring and measurement of immunological status (in addition to adverse events) to keep tabs on immunity levels and duration of retainment. This is especially concerning given continuously emerging virus variants.
Though the US Food and Drugs Administration (FDA) currently does not recommend such tests to measure immunity levels post vaccination, the information could be stored by health authorities for its own internal use, instead of public self-management.
As more research on COVID-19 antibody tests emerge, this information, when combined with other patient information and links to virus variants can potentially help measure the success towards “herd immunity”, serve as a basis for vaccine passports implementation, and can help provide guidance for further vaccine types to be procured and other pandemic management strategies.
Also note that undocumented foreign population are not included in timeline projections, which, subject to their actual numbers, could add one to two months in estimates, and must be included in the vaccination programme. No one is safe until everyone is safe. – July 17, 2021
Ameen Kamal is the Head of Science & Technology at EMIR Research, an independent think tank focused on strategic policy recommendations based on rigorous research.
The views expressed are solely of the author and do not necessarily reflect those of Focus Malaysia.
